JupiteX Get the app
Science & Technology17 Nov 2026 · about 7 min

Chinese scientist sacked after child died in gene-editing trial

The brief

Investigators found that Zilong Qiu was mainly responsible for the research and that his team failed to follow regulations. The case matters because the therapy went ahead despite a safety warning, and the hospital’s oversight also fell short. The investigation found that the clinical researcher was not told about the warning promptly. About a month before treatment, the team received results showing that monkeys had sustained liver damage in a preclinical toxicology study. Investigators said the early warning in the safety report was not given high attention. Qiu’s team did not inform the clinical researcher at Xinhua Hospital in a timely fashion. A lawyer quoted in the article said the trial should not have gone ahead with evidence of harm in animals. Qiu was sacked as deputy director of the Songjiang Research Institution. He and another team member were barred from leading or taking part in science projects for five years and entered in a national research-integrity database. The clinical researcher was removed as head of research at Xinhua Hospital. The hospital and university were reprimanded and told to review their practices.

01

Why was the researcher who led the gene-editing trial sacked?

Investigators found that Zilong Qiu was mainly responsible for the research and that his team failed to follow regulations. The case matters because the therapy went ahead despite a safety warning, and the hospital’s oversight also fell short. The investigation found that the clinical researcher was not told about the warning promptly.

About a month before treatment, the team received results showing that monkeys had sustained liver damage in a preclinical toxicology study. Investigators said the early warning in the safety report was not given high attention. Qiu’s team did not inform the clinical researcher at Xinhua Hospital in a timely fashion. A lawyer quoted in the article said the trial should not have gone ahead with evidence of harm in animals.

Qiu was sacked as deputy director of the Songjiang Research Institution. He and another team member were barred from leading or taking part in science projects for five years and entered in a national research-integrity database. The clinical researcher was removed as head of research at Xinhua Hospital. The hospital and university were reprimanded and told to review their practices.

02

What treatment did the six-year-old girl receive, and what happened after she received it?

The girl received an experimental gene-editing therapy developed for Snijders Blok–Campeau syndrome, a rare neurodevelopmental disorder. The treatment was intended for a six-year-old, but the article does not describe its clinical benefit. Her death after the treatment makes the case a stark example of the risks involved in testing an experimental therapy in a child.

The treatment was carried by a viral vector. The team injected it into the girl’s spine, and it then travelled to her brain. The article reports that she received the therapy at Xinhua Hospital in Shanghai in March 2025. It does not give further details about the treatment’s design, dose, or the medical complications that led to her death.

The Shanghai government investigated the trial and found failures in safety communication and hospital assessment. The investigation also found that the consent form did not mention death as a possible risk. The institutions involved were reprimanded and told to examine their practices. These details show why clear risk information and careful oversight matter when experimental treatments are given to patients.

03

How much warning was there before treatment: what harm did monkey tests reveal, and when did the team receive those results?

The safety warning came from a preclinical toxicology study in monkeys. The tests showed that the monkeys sustained liver damage. This mattered because the results were available before the experimental therapy was given to the six-year-old girl, and investigators concluded that the warning did not receive proper attention.

According to the reporting cited in the article, Qiu’s team received the results about a month before the girl’s treatment. Investigators found that the team did not inform the researcher responsible for clinical research at Xinhua Hospital in a timely fashion. As a result, the “early warning signal” in the safety report was not given high attention, the government statement said.

The article does not specify when the monkey study itself was conducted, how many monkeys were involved, or how severe their liver damage was. It does state that the treatment proceeded in March 2025. A lawyer quoted in the report said the trial should not have gone ahead once animal tests showed evidence of harm. The episode highlights the importance of rapidly sharing safety findings before human trials.

04

What penalties did the researchers and institutions face after the investigation?

The investigation led to penalties for researchers, hospital staff, and the institutions involved. Its findings pointed to failures in handling a safety warning and in assessing the proposed clinical trial. The actions were intended to address those failures and signal that research oversight matters, as a lawyer quoted in the article said.

Qiu was sacked from his deputy-director position at the Songjiang Research Institution. Another member of his team, a deputy researcher at Xinhua Hospital, was also dismissed. Both were barred from leading or participating in science projects for five years and added to a national database of people and organizations responsible for serious research-integrity breaches. The clinical researcher was removed as head of research at Xinhua Hospital.

Shanghai Jiao Tong University School of Medicine and Xinhua Hospital were reprimanded and instructed to examine their practices. Two members of the hospital’s ethics committee were given penalties, though the statement did not specify what those penalties were. The article also says China increased oversight of investigator-initiated trials in May, a change that may help prevent similar cases.

05

What are investigator-initiated trials, and how can they let treatments be tested faster?

Investigator-initiated trials, or IITs, are a fast-track pathway described in the article. They allow researchers and biotech companies to test therapies in hospitals without supervision from the country’s regulators. The pathway can make testing faster by letting researchers begin work in hospital settings without going through the same regulatory supervision described in the article.

The trial involving the six-year-old girl took place under this pathway. It tested an experimental gene-editing therapy for Snijders Blok–Campeau syndrome. Investigators found that Qiu’s team did not promptly share monkey toxicology results showing liver damage, while Xinhua Hospital approved the trial without receiving extra safety materials requested by its ethics committee. Those failures show why speed must be matched by careful checks.

The article describes China’s biotechnology industry as rapidly growing and says clinical oversight has not always kept pace. The Chinese government increased oversight of IITs in May. A lawyer quoted in the report said this should help prevent similar cases in future. The article does not detail the specific new oversight rules, so it is not possible to say exactly how they will change trial procedures.

06

What is gene editing, and how can a viral vector carry a treatment into the body?

Gene editing is a way of making targeted changes to genetic material in cells. That general definition comes from established scientific knowledge; the article does not describe which genetic change this experimental therapy was designed to make. Gene-editing treatments matter because they aim to act on biological instructions within cells, but the article focuses on how this trial was conducted and overseen.

A viral vector is a delivery vehicle based on a virus, modified for use in carrying material into the body or cells. The article says this therapy was carried by a viral vector, injected into the girl’s spine, and then travelled to her brain. It does not say which virus was used, what the vector carried in detail, or how the editing machinery worked.

The therapy was developed for Snijders Blok–Campeau syndrome and was experimental. After the girl received it at Xinhua Hospital in March 2025, she died of medical complications. Investigators later found shortcomings in safety reporting and trial assessment. Those case details do not establish how gene editing or viral vectors generally work in every treatment; they describe this specific trial.

07

Why do researchers normally study a treatment’s safety before testing it in people?

Researchers study a treatment’s safety before testing it in people to look for possible harms and gather evidence that can guide decisions about human trials. This is established scientific practice; the article gives a specific example rather than a full account of how safety testing works. Such checks matter because an early warning can affect whether, when, or how a trial proceeds.

In this case, a preclinical toxicology study found liver damage in monkeys. Qiu’s team received the results about a month before the girl received the experimental therapy. Investigators found that the team did not tell the clinical researcher at Xinhua Hospital promptly, and that the early warning in the safety report did not receive high attention. A lawyer quoted in the article said the trial should not have gone ahead if animal tests showed evidence of harm.

The investigation also found that the hospital approved the trial without receiving extra materials requested by its ethics committee. The family’s consent form did not mention death as a risk. The case illustrates that safety evidence must be assessed and communicated, and that families need relevant risk information before consenting. The article says China increased oversight of investigator-initiated trials in May.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web